Showing results (11-20 of 38) with videos related to
Sort By:
Pageof 4
Mutation Research|May 1, 1994
The nature of X-ray-induced mutations in mature sperm and spermatogonial cells of Drosophila melanogasterJ C Eeken, A W de Jong, M Loos, et al.Cancer Chemotherapy and Pharmacology|March 9, 2023
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancerLoek A W de Jong, Marie Lambert, Nielka P van Erp, et al.Cancer Chemotherapy and Pharmacology|February 3, 2026
Etoposide dosing challenges in a testicular cancer patient with hepatic impairment and drug-drug interactions-a case reportCatharina J P Op 't Hoog, Loek A W de Jong, Joost Sijm, et al.Arthritis and Rheumatism|October 15, 2003
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisSolbritt Rantapää-Dahlqvist, Ben A W de Jong, Ewa Berglin, et al.Journal of Wildlife Diseases|November 11, 2009
Herpesvirus in bottlenose dolphins (Tursiops truncatus): cultivation, epidemiology, and associated pathologyCornelis E van Elk, Marco W G van de Bildt, Antonius A W de Jong, et al.British Journal of Clinical Pharmacology|December 2, 2025
Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistatAnnemieke M Peters van Ton, Nielka P van Erp, Annenienke C van de Ven, et al.Chest|July 22, 2008
Mannose-binding lectin genotypes in susceptibility to community-acquired pneumoniaHenrik Endeman, Bjorn L Herpers, Ben A W de Jong, et al.Journal of Immunological Methods|January 28, 2009
Hemolytic assay for the measurement of functional human mannose-binding lectin: a modification to avoid interference from classical pathway activationBjorn L Herpers, Ben A W de Jong, Bertie Dekker, et al.Molecular Immunology|August 4, 2005
Coding and non-coding polymorphisms in the lectin pathway activator L-ficolin gene in 188 Dutch blood bank donorsBjorn Lars Herpers, Marie-Monique Immink, Ben A W de Jong, et al.Cancer Chemotherapy and Pharmacology|October 22, 2025
Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy-A case reportLotte M G Hulskotte, Loek A W de Jong, Alwin D R Huitema, et al.Pageof 4